According to the Infectious Diseases Society of America (IDSA), antibiotic-resistant bacteria are becoming an increased problem in hospitals and communities due to the lack of antibacterial options currently available. Throughout the world, many Gram-positive and Gram-negative pathogens are growing more resistant to antibiotics currently on the market. The goal of this journal article is to raise awareness for the global antibiotic crisis and to hopefully encourage the community and legislative to raise funds in order to increase antibiotic production. The “ESKAPE” pathogens that are currently causing the majority of infections and are resistant to current antibiotics are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
…show more content…
Doripenem is a carbapenem that has better in vitro potency against P.aeruginosa than meropenem does due to its activity against extended-spectrum beta-lactamase, which ultimately means that it could potentially be effective in clinical aspects. There have also been some positive results in a few phase 3 studies for telavancin, ceftobiprole, and cethromycin, despite their regulatory delays. On the other hand, a promising oral and intravenous aminomethylcycline PTK-0796, completed its phase 2 study versus linezolid for treatment of cSSSI. It was found to be similar to tigecycline’s spectrum, showing positive indications for MRSA, VRE, and Gram-negative pathogens, such as A. baumannii being present in its spectrum. Therefore, these results indicate that this drug could potentially be used in treating Gram-negative infections. There are also two anti-Gram positive oral drugs being tested; one is called iclaprim and the other is called RX-1741. Iclaprim behaves similarly to the drug trimethoprim and RX-1741 is a second-generation oxazolidinone. Another drug that has potential against Gram-negative infections, such as Acinetobacter species, is called BAL 30376 and is classified as a beta-lactam–beta-lactamase inhibitor. However, the drug telavancin is the only drug with a known novel mechanism of
Doripenem is a carbapenem that has better in vitro potency against P.aeruginosa than meropenem does due to its activity against extended-spectrum beta-lactamase, which ultimately means that it could potentially be effective in clinical aspects. There have also been some positive results in a few phase 3 studies for telavancin, ceftobiprole, and cethromycin, despite their regulatory delays. On the other hand, a promising oral and intravenous aminomethylcycline PTK-0796, completed its phase 2 study versus linezolid for treatment of cSSSI. It was found to be similar to tigecycline’s spectrum, showing positive indications for MRSA, VRE, and Gram-negative pathogens, such as A. baumannii being present in its spectrum. Therefore, these results indicate that this drug could potentially be used in treating Gram-negative infections. There are also two anti-Gram positive oral drugs being tested; one is called iclaprim and the other is called RX-1741. Iclaprim behaves similarly to the drug trimethoprim and RX-1741 is a second-generation oxazolidinone. Another drug that has potential against Gram-negative infections, such as Acinetobacter species, is called BAL 30376 and is classified as a beta-lactam–beta-lactamase inhibitor. However, the drug telavancin is the only drug with a known novel mechanism of